2. CONFIDENTIAL2 Plasticell Ltd – Company Overview: London-based stem cell biotechnology company Founded 2002 Mostly angel funded Since 2003 obtained 1 DTI and 9TSB grants Focus: Effective Differentiation of Stem Cells Approach: Bead-based High Throughput Screening Technology: Combinatorial Cell Culture™ Business model – Service model for cells used in research – Partnering model for cells used in therapy

3. CONFIDENTIAL3 Plasticell Ltd – Company Overview: 2002- Company formed by Yen Choo - Patent filed (now granted EP, AU, SP, US, JP) 2004- First round fundraising (3) 2007- Fundraising (4) - DTI grant 2008- GSK contract (5) - TSB grant 2009- Fundraising (5) 2010- Fundraising (7) - Progenitor Labs split - Launch of Combicult V2 2011- 2 TSB grants (9)

4. CONFIDENTIAL4 Cell Therapy Cell Tools Regenerative Drugs Blastocyst Somatic Cell hESC iPSC The Stem Cell Platform Adult stem cells Adult tissue $1.3 bn $60m - hepatocytes $117m - Eltrombopag

5. CONFIDENTIAL The Differentiation Problem A B C D E F 5 Reproducible Safe High yield Scaleable Affordable

6. CONFIDENTIAL 6 Combinatorial Cell Culture™ Screen beads for differentiated cells Seed stem cells on beads Shuffle beads stepwise through multiple media Trace cell culture history to discover new protocols

7. CONFIDENTIAL Module 2: Split-Pool Beads are shuffled through combinations of media (and tagged) using a novel device Module 4: Hit Sorting Hit beads are individually sorted into the wells of a 96-well plate using a large particle flow sorter Module 7: Bioinformatics The large amount of data is analysed to predict the optimal protocols. Module 8: Validation In this module the optimal protocols are validated individually either in 2-D culture or on beads. Module 1 : Cells Stem cells are seeded onto thousands of beads. Module 3: Screening All beads are screened for those bearing differentiated stem cells (Hits). Module 6: Tag analysis Tags from each hit are analysed by FACS and tag IDs matched to the corresponding differentiation media Module 5: Visualisation and Tag release Sorted beads are imaged by fluorescence microscopy, after which the tags are released CombiCult™ v2.0 – Launched 2010 7

8. CONFIDENTIAL8 TSB Grants GRANTProject Value £ 2007CombiCult Technology v2.01,755,934 2008Osteocytes and Chondrocytes1,293,154 2009Osteocyte scale up97,998 2010Reporter Cells for CombiCult95,800 2011Hepatocyte manufacturing32,884 2011IP Audit10,000 2011CombiCult v3.0 for GMP1,489,973 2011Cellzome/Pfizer project1,418,852 2012Combicult for Bioprocessing33,080 Total6,227,675

9. CONFIDENTIAL9 KTN involvement Grant H28G included CIKTN as a partner (2007) Advising on the competition scope Building consortium Reviewing grant proposal Including the catchphrases Project management 10110 and Feasibility Study (2011) Input into application Consortium building Access to project management support Awareness of funding calls Introductions to potential partners (e.g. Lonza, LGC) Advice on TSB strategy

10. CONFIDENTIAL10 CIKTN and TSB Impact on Plasticell Access industry and academic expertise High profile academic validation of the science Possible commercialisation route through partners Introductions to new collaborators and potential customers Grants: Build Combicult technology platform – e.g. Labryinth Formulate media product (licenced to major distributor) Progress commercialisation of cell products (scale-up bone; liver cells) GMP cell manufacture Leveraged grants to obtain investment (esp. angel investment)